back to US directory
us clinical guidance

HIV screening and diagnostic testing in primary care

USPSTF universal screening, pregnancy testing, repeat risk-based testing, acute-HIV recognition and rapid linkage to care.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adolescents, adults and pregnant patients in primary care who need routine screening, risk-based repeat testing or diagnostic evaluation. This page does not replace the detailed CDC laboratory algorithm, occupational and nonoccupational PEP, PrEP assessment, neonatal testing or management of established HIV. Testing should be voluntary, confidential and accessible without stigma.
sources for this section:USPSTF HIV 2019

The Bottom Line

  • USPSTF recommends HIV screening for adolescents and adults aged 15 to 65 years, for younger or older people at increased risk, and for every pregnant patient whose status is not known.
  • Use opt-out screening in routine care where applicable and repeat testing according to ongoing risk, local epidemiology and patient request rather than relying on identity labels.
  • Follow the current CDC laboratory sequence beginning with an HIV-1/2 antigen–antibody assay and supplemental differentiation testing, with nucleic-acid testing to resolve discordance or suspected acute infection.
  • Link a confirmed patient rapidly to antiretroviral care and support; modern treatment benefits the patient and sustained viral suppression prevents sexual transmission.
sources for this section:USPSTF HIV 2019

Practical clinical workflow

1
Normalize testing, obtain consent under applicable law, assess previous tests and window period, and ask about sexual and injection exposure, pregnancy, STI, PEP, PrEP and symptoms of acute retroviral illness.
2
Select laboratory or rapid testing appropriate to urgency and exposure timing; add HIV RNA when acute infection is plausible despite a nonreactive or indeterminate screening result.
3
Communicate results privately with clear interpretation, arrange confirmatory steps without delay, and provide immediate linkage, baseline clinical assessment and partner-services information for a new diagnosis.
4
For a negative result, determine whether repeat testing, PrEP, PEP, STI screening, harm-reduction services or vaccination is indicated and document the plan without moral judgment.
sources for this section:USPSTF HIV 2019

Safety boundaries and escalation

  • A high-risk exposure within the PEP window requires immediate PEP evaluation; do not wait for completion of the routine testing sequence before starting an indicated time-critical regimen.
  • Fever, rash, pharyngitis, lymphadenopathy or aseptic-meningitis symptoms after recent exposure can represent acute HIV; a negative antibody-only test may be falsely reassuring.
  • A reactive point-of-care screen is preliminary and requires the diagnostic algorithm, but linkage work should begin immediately and communication must avoid labeling it as confirmed prematurely.
  • Unknown status during labor requires rapid testing and obstetric, pediatric and infectious-disease action to reduce perinatal transmission under current US guidance.
sources for this section:USPSTF HIV 2019

Localization

USPSTF screening is a Grade A US preventive recommendation. Consent, minors’ access, result reporting and partner services vary by state, while laboratory practice follows federal and CDC standards.
sources for this section:USPSTF HIV 2019

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. U.S. Preventive Services Task ForceHuman Immunodeficiency Virus (HIV) Infection: ScreeningFinal Recommendation Statement; Grade A · published 2019-06-11 · accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.